Expression of concern
Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: An indirect treatment comparison meta-analysis
Paper Information
Record ID:
35137
Journal:
Publication Date:
July 01, 2014
Retraction Date:
January 24, 2022
(3.8 years years ago)
Subjects:
Broad Categories:
Medicine
Medicine
Institutions:
- Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada b Stanford Prevention Research Center, Stanford University, Stanford, CA, United States
- Faculty of Health Sciences, University of Ottawa, Ottawa, Ontario, Canada
- Division of Gastroenterology, University of Alberta, Canada
- Division of Gastroenterology, McMaster University, Hamilton, Ontario, Canada
Countries:
Article Type:
Publisher:
Oxford Academic
Open Access:
Yes
PubMed ID:
Retraction PubMed ID:
Expression of concern Details
Retraction Reasons:
Nature of Retraction:
Expression of concern
Retraction Notice:
10.1093/ecco-jcc/jjab227Additional Notes:
See also: https://doi.org/10.1093/ecco-jcc/jjab225 Journal was previously published by Elsevier until 2015.
Citations (77)
77
Total Citations10
Post-Retraction(13.0%)
66
Pre-Retraction1
Same DayPost-Retraction Citation Analysis
0
Within 30 days
3
Within 1 year
3
After 2+ years
1123
Days since retraction (latest)
Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease
Nikola Mitrev, Rupert W. Leong
Expert Opinion on Drug Safety
Published: Dec 2016
27 citations
27 citations
1875 days before retraction
Paper citing Adalimumab versus infliximab for the treatment of ...
Unknown Authors
Unknown Journal
Published: Sep 2016
1963 days before retraction
Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel Diseases
Subrata Ghosh, William J. Sandborn, Jean‐Frédéric Colombel et al. (13 authors)
Inflammatory Bowel Diseases
Open Access
Published: Aug 2016
18 citations
18 citations
1972 days before retraction
Psoriasis and inflammatory bowel disease: links and risks
Ioannis D. Bassukas, Georgios Gaitanis, Κωνσταντίνος Κατσάνος et al. (6 authors)
Psoriasis Targets and Therapy
Open Access
Published: Jul 2016
63 citations
63 citations
2033 days before retraction
Adalimumab for Moderately to Severely Active Ulcerative Colitis: A Systematic Review and Meta-Analysis
Xinlin Chen, Jiangtao Hou, Yujie Yuan et al. (12 authors)
BioDrugs
Published: Apr 2016
13 citations
13 citations
2098 days before retraction
Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network
Hélène Vallet, P. Sève, Lucie Biard et al. (26 authors)
Arthritis & Rheumatology
Open Access
Published: Mar 2016
168 citations
168 citations
2131 days before retraction
Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States
William J. Sandborn, Atsushi Sakuraba, Anthony Wang et al. (8 authors)
Current Medical Research and Opinion
Published: Mar 2016
29 citations
29 citations
2139 days before retraction
Recent insights into the molecular pathogenesis of Crohn's disease: a review of emerging therapeutic targets
Mircea Diculescu, Teodora Manuc, Mircea Mănuc
Clinical and Experimental Gastroenterology
Open Access
Published: Mar 2016
30 citations
30 citations
2155 days before retraction
How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease
Parambir S. Dulai, Siddharth Singh, Niels Vande Casteele et al. (5 authors)
Inflammatory Bowel Diseases
Open Access
Published: Feb 2016
21 citations
21 citations
2183 days before retraction
Positioning Therapy for Ulcerative Colitis
Ari Grinspan, Asher Kornbluth
Current Gastroenterology Reports
Published: Jul 2015
13 citations
13 citations
2396 days before retraction
Paper citing Adalimumab versus infliximab for the treatment of ...
Unknown Authors
Unknown Journal
Published: Jun 2015
2429 days before retraction
Clinical outcome of adalimumab therapy in patients with ulcerative colitis previously treated with infliximab: a Danish single-center cohort study
Katrine Risager Christensen, Casper Steenholdt, Jørn Brynskov
Scandinavian Journal of Gastroenterology
Published: Apr 2015
20 citations
20 citations
2481 days before retraction
The economics of adalimumab for ulcerative colitis
Feng Xie
Expert Review of Pharmacoeconomics & Outcomes Research
Published: Mar 2015
2 citations
2 citations
2492 days before retraction
Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs
Kristian Thorlund, Eric Druyts, Kabirraaj Toor et al. (4 authors)
Expert Review of Gastroenterology & Hepatology
Published: Mar 2015
56 citations
56 citations
2510 days before retraction
Factors Associated with Mucosal Healing in Patients with Ulcerative Colitis in Clinical Remission
Hai Yun Shi, Francis K.L. Chan, Steven Woon–Choy Tsang et al. (14 authors)
Inflammatory Bowel Diseases
Open Access
Published: Mar 2015
7 citations
7 citations
2518 days before retraction
Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitis
Kabirraaj Toor, Eric Druyts, Jeroen P. Jansen et al. (4 authors)
Journal of Medical Economics
Open Access
Published: Jan 2015
16 citations
16 citations
2553 days before retraction
Ulcerative Colitis: What is the Optimal Treatment Goal and How Do We Achieve It?
Edith Y. Ho, Fabio Cominelli, Jeffry Katz
Current Treatment Options in Gastroenterology
Published: Jan 2015
11 citations
11 citations
2556 days before retraction
Exploration of post-market evidence of effectiveness and safety of TNF-alpha inhibitors in Crohn's and colitis
Erika MacDonald
Unknown Journal
Published: Jan 2015
2580 days before retraction
Impact of thiopurines and anti-tumour necrosis factor therapy on hospitalisation and long-term surgical outcomes in ulcerative colitis
Christopher Alexakis
World Journal of Gastrointestinal Surgery
Open Access
Published: Jan 2015
5 citations
5 citations
2580 days before retraction
What Is the Right Dosage
Pierre Michetti
Frontiers of gastrointestinal research
Open Access
Published: Jan 2015
2580 days before retraction
The ‘Ideal' Anti-TNF Patient: Indications for Anti-TNF Therapy in Ulcerative Colitis
Tadakazu Hisamatsu
Frontiers of gastrointestinal research
Open Access
Published: Jan 2015
2580 days before retraction
Biologics in the management of ulcerative colitis – comparative safety and efficacy of TNF-α antagonists
Anita Afzali, Rebecca Fausel
Therapeutics and Clinical Risk Management
Open Access
Published: Jan 2015
37 citations
37 citations
2580 days before retraction
Guía de práctica clínica para el diagnóstico y tratamiento de la colitis ulcerativa en población adulta Clinical practice guideline for the diagnosis and management of adult patients with Ulcerative Colitis
Fabián Juliao Baños, Carlos Fernando, Andrea Grillo et al. (15 authors)
Unknown Journal
Published: Jan 2015
2580 days before retraction
Cutaneous Adverse Reactions during Anti-Tnf Alpha Treatment for Inflammatory Bowel Diseases: The Experience of the Dermatology Clinic of Cagliari
Atzori L Mantovani L
Journal of Pharmacovigilance
Open Access
Published: Jan 2015
7 citations
7 citations
2580 days before retraction
Incorporating alternative design clinical trials in network meta-analyses
Eric Druyts, Kristian Thorlund, Kabirraaj Toor et al. (5 authors)
Clinical Epidemiology
Open Access
Published: Dec 2014
7 citations
7 citations
2611 days before retraction
Ulcerative Colitis
Joseph D. Feuerstein, Adam S. Cheifetz
Mayo Clinic Proceedings
Open Access
Published: Sep 2014
307 citations
307 citations
2695 days before retraction
Systematic review with network meta‐analysis: the efficacy of anti‐<scp>TNF</scp> agents for the treatment of Crohn's disease
Ryan W. Stidham, T. C. H. Lee, Peter Higgins et al. (10 authors)
Alimentary Pharmacology & Therapeutics
Open Access
Published: Apr 2014
186 citations
186 citations
2836 days before retraction
Quick Stats
Total Citations:
77
Years Since Retraction:
3.8 years
Open Access:
Yes
Last Checked:
Jul 24, 2025